Effects of resveratrol on proliferation and invasion of lung cancer 95D cells

doi:10.3760/cma.j.issn.1673-422X.2018.12.001

Abstract

Abstract: ObjectiveTo study the effects of resveratrol on the proliferation and invasion capacity of human lung adenocarcinoma 95D cells. MethodsHuman lung adenocarcinoma 95D cells were treated with 0, 10, 20, 40, 80 μmol/L resveratrol and treated with 0 μmol/L as the control group. The proliferation level of 95D cells was measured by methyl thiazolyl tetrazolium (MTT). Cell cycle and apoptosis were detected by flow cytometry. Cell adhesion rate was determined by in vitro adhesion test. Cell invasiveness was measured by Transwell chamber. The expressions of matrix metalloproteinase2 (MMP2) and tissue inhibitior of metalloproteinase2 (TIMP2) were determined by fluorescent immunocytochemistry. ResultsWhen the 95D cells were treated with resveratrol for 72 h, the cell proliferation rates in groups treated with 0, 10, 20, 40, 80 μmol/L resveratrol were 100%, (82.23±0.33)%, (62.45±0.27)%, (49.89±0.43)%, (45.11±0.35)% respectively, with a significant difference (F=87.830, P=0.002). The proliferation rates of 95D cells in the 10, 20, 40, 80 μmol/L resveratrol groups were significantly inhibited compared with the control group (P=0.017, P<0.001, P<0.001, P<0.001). When the 95D cells were treated for 48 h, the apoptosis rates of cells in each group were 0, (34.90±0.91)%, (41.33±0.13)%, (45.47±0.87)%, (59.46±0.59)% respectively, with a significant difference (F=21.032, P=0.002). The apoptosis rates of 95D cells in the 10, 20, 40, 80 μmol/L resveratrol groups were significantly increased compared with the control group (P=0.001, P<0.001, P<0.001, P<0.001). When the 95D cells were treated for 48 h, the S phase cell percentages in each group were (18.12±0.62)%, (38.33±0.62)%, (54.15±0.74)%, (44.85±0.82)%, (50.01±0.35)% respectively, with a significant difference (F=104.156, P=0.001). The S phase cell percentages in the 10, 20, 40, 80 μmol/L resveratrol groups were significantly higher compared with the control group (P=0.001, P<0.001, P<0.001, P<0.001). When the 95D cells were treated for 24 h, the cell adhesion rates in each group were 100%, (87.41±0.02)%, (84.32±0.03)%, (68.23±0.04)%, (63.01±0.02)% respectively, with a significant difference (F=13.760, P<0.001). The cell adhesion rates in the 20, 40, 80 μmol/L resveratrol groups were significantly inhibited compared with the control group (P=0.035, P<0.001, P<0.001), while the 10 μmol/L resveratrol group had no significant difference compared with the control group (P=0.058). When the 95D cells were treated for 24 h, the cell invasion rates in each group were 100%, (97.01±0.03)%, (74.89±0.07)%, (34.07±0.03)%, (14.65±0.02)% respectively, with a significant difference (F=39.382, P=0.001). The cell invasion rates in the 20, 40, 80 μmol/L groups were significantly inhibited compared with the control group (P=0.012, P<0.001, P<0.001), while the 10 μmol/L resveratrol group had no significant difference compared with the control group (P=0.881). When the 95D cells were treated for 48 h, MMP2 protein expression was decreased in the 20 mol/L group, while TIMP2 protein expression was increased compared with the control group. ConclusionResveratrol can inhibit the proliferation of human lung adenocarcinoma 95D cells and has effect of antitumor cell invasiveness, and its mechanism may involve twoway regulation of MMP2/TIMP2 expression.

Key words: Lung neoplasms, Cell proliferation, Cell adhesion, Neoplasm invasiveness;, Resveratrol

Chen Haixia. Effects of resveratrol on proliferation and invasion of lung cancer 95D cells[J]. Journal of International Oncology, 2018, 45(12): 705-710.

References

［1］ Das DK, Maulik N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine［J］. Mol Interv, 2006, 6(1): 3647. DOI: 10.1124/mi.6.1.7. ［2］ Nichols JA, Katiyar SK. Skin photoprotection by natural polyphenols: antiinflammatory, antioxidant and DNA repair mechanisms［J］. Arch Dermatol Res, 2010, 302(2): 7183. DOI: 10.1007/s0040300910013. ［3］ Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a highcalorie diet［J］. Nature, 2006, 444(7117): 337342. DOI: 10.1038/nature05354. ［4］ Hao HD, He LR. Mechanisms of cardiovascular protection by resveratrol［J］. J Med Food, 2004, 7(3): 290298. DOI: 10.1089/jmf.2004.7.290. ［5］ Delmas D, Lancon A, Colin D, et al. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer［J］. Curr Drug Targets, 2006, 7(4): 423442. ［6］ Udeniqwe CC, Ramprasath VR, Aluko RE, et al. Potential of resveratrol in anticancer and antiinflammatory therapy［J］. Nutr Rev, 2008, 66(8): 445454. DOI: 10.1111/j.17534887.2008.00076.x. ［7］ Saiko P, Szakmary A, Jaeger W, et al. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?［J］. Mutat Res, 2008, 658(12): 6894. DOI: 10.1016/j.mrrev.2007.08.004. ［8］ Weng CJ, Yang YT, Ho CT, et al. Mechanisms of apoptotic effects induced by resveratrol, dibenzoylmethane, and their analogues on human lung carcinoma cells［J］. J Agric Food Chem, 2009, 57(12): 52355243. DOI: 10.1021/jf900531m. ［9］ Zhou R, Fukui M, Choi HJ, et al. Induction of a reversible, noncytotoxic Sphase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection［J］．Br J Pharmacol, 2009, 158(2): 462474. DOI: 10.1111/j.14765381.2009.00268.x. ［10］ Vanamala J, Reddivari L, Radhakrishnan S, et al．Resveratrol suppresses IGF1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF1R/Wnt and activation of p53 signaling pathways［J］．BMC Cancer, 2010, 10: 238. DOI: 10.1186/1471240710238. ［11］ Hudson TS, Hartle DK, Hursting SD, et al. Inhibition of prostate cancer growth by muscadine grape skin extract and resveratrol through distinct mechanisms［J］. Cancer Res, 2007, 67(17): 8396 8405. DOI: 10.1158/00085472.CAN064069. ［12］李玉林. 病理学［M］. 北京: 人民卫生出版社, 2006: 103. ［13］ Li T, Fan GX, Wang W, et al. Resveratrol induces apoptosis, influences IL6 and exerts immunomodulatory effect on mouse lymphocytic leukemia both in vitro and in vivo［J］. Int Immunopharmacol, 2007, 7(9): 12211231. DOI: 10.1016/j.intimp.2007.05.008. ［14］ Delmas D, Jannin B, Cherkaoui Malki M, et al. Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines［J］. Oncol Rep, 2000, 7(4): 847852. ［15］ Kim YA, Choi BT, Lee YT, et al. Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF7 cells［J］. Oncol Rep, 2004, 11(2): 441446. ［16］ Cockett MI, Murphy G, Birch ML, et al. Matrix metalloproteinases and metastatic cancer［J］. Biochem Soc Symp, 1998, 63: 295313. ［17］ Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment［J］. Cell, 2010, 141(1): 5267. DOI: 10.1016/j.cell.2010.03.015. ［18］ Nol A, Jost M, Maquoi E. Matrix metalloproteinases at cancer tumorhost interface［J］. Semin Cell Dev Biol, 2008, 19(1): 5260. DOI: 10.1016/j.semcdb.2007.05.011. ［19］ Bourboulia D, StellerStevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion［J］. Semin Cancer Biol, 2010, 20(3): 161168. DOI: 10.1016/j.semcancer.2010.05.002. ［20］ Weng CJ, Wu CF, Huang HW, et al. Evaluation of antiinvasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells［J］. J Agric Food Chem, 2010, 58(5): 28862894. DOI: 10.1021/jf904182y. ［21］ Athar M, Back JH, Kopelovich L, et al. Multiple molecular targets of resveratrol: anticarcinogenic mechanisms［J］. Arch Biochem Biophys, 2009, 486(2): 95102.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Ren Lu, Xie Xiaoli, Zhang Kun, Wang Lijuan. Effects and mechanisms of dihydroartemisinin combined with carfilzomib on the activity， proliferation， and apoptosis of multiple myeloma cells [J]. Journal of International Oncology, 2024, 51(3): 129-136.
[3]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[4]	Xiang Yuling, Tan Jiajie, Xiong Yuanguo, Zhao Lirong, Li Chen, Zhang Hong. Effects of Anhydroicaritin on the proliferation， migration and apoptosis of hepatocellular carcinoma cells [J]. Journal of International Oncology, 2023, 50(9): 513-519.
[5]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[6]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[7]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[8]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[9]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[10]	Lian Haiwei, Yang Shuorui, Liu Renzhong. Mechanism study on regulation of glioblastoma cell proliferation and apoptosis by sciadopitysin combined with CX-4945 through Notch1 pathway [J]. Journal of International Oncology, 2022, 49(6): 321-326.
[11]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[12]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[13]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing. MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2 [J]. Journal of International Oncology, 2022, 49(4): 193-198.
[14]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[15]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.